Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

In the latest close session, Adma Biologics (ADMA) was up +2.39% at $17.13. This change outpaced the S&P 500's 0.14% gain on the day. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 0.38%. Shares of the infectious disease drug developer have depreciated by 5.69% over the course of the past month, underperforming the Medical sector's loss of 1.94%, and the S&P 500's gain of 5.35%.Analysts and investors alike will be keeping a close eye on the performance of Adma Biologics in its upcoming earnings disclosure. The company is expected to report EPS of $0.14, up 7.69% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $121.1 million, up 12.98% from the year-ago period. For the full year, the Zacks Consensus Estimates are projecting earnings of $0.61 per share and revenue of $505.8 million, which would represent changes of +24.49% and +18.61%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 8.27% lower. Adma Biologics is currently a Zacks Rank #4 (Sell). Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 27.43. This signifies a premium in comparison to the average Forward P/E of 17.79 for its industry. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 86, positioning it in the top 35% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Should You Invest in ADMA Biologics Inc (ADMA)?Before you invest in ADMA Biologics Inc (ADMA), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks